J
Janice L. Wheeler
Researcher at Eisai
Publications - 5
Citations - 1032
Janice L. Wheeler is an academic researcher from Eisai. The author has contributed to research in topics: Eritoran & Lipid A. The author has an hindex of 4, co-authored 4 publications receiving 946 citations.
Papers
More filters
Journal ArticleDOI
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol,Jagadish Gogate,Mary B. Roberts,Mary B. Roberts,Janice L. Wheeler,Jean Louis Vincent +29 more
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Journal ArticleDOI
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Mark Tidswell,William Tillis,Steven P. LaRosa,Melvyn Lynn,AE Wittek,Richard Kao,Janice L. Wheeler,Jagadish Gogate,Steven M. Opal +8 more
TL;DR: The observed trend toward a lower mortality rate at the 105-mg dose, in subjects with severe sepsis and high predicted risk of mortality, should be further investigated.
Journal ArticleDOI
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
Melvyn Lynn,Daniel P. Rossignol,Janice L. Wheeler,Richard Kao,Carlos Perdomo,Robert J. Noveck,Ramon Vargas,Tony D’Angelo,Sandra Gotzkowsky,F. Gilbert McMahon +9 more
TL;DR: It is demonstrated that E5564 blocks the effects of LPS in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinicalSepsis.
Journal ArticleDOI
Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia
Melvyn Lynn,Y. Nancy Wong,Janice L. Wheeler,Richard Kao,Carlos Perdomo,Robert J. Noveck,Ramon Vargas,Tony D’Angelo,Sandra Gotzkowsky,F. Gilbert McMahon,Kishor M. Wasan,Daniel P. Rossignol +11 more
TL;DR: In this paper, the authors evaluated the pharmacodynamic activity of 4-and 72-h infusions of E5564 into normal volunteers and showed that E55 64 completely blocked the effects of endotoxin in a human model of clinical sepsis.
Posted ContentDOI
COVID MED - An Early Pandemic Trial of Losartan for Hospitalized COVID-19 Patients
David E. Freilich,Jennifer M. Victory,Paula Jenkins,Janice L. Wheeler,George M. Vail,Erik P. Riesenfeld,Philip Cross,Claire E. Gilmore,Amanda E. Schworm,Umesha Boregowda,Farah Deshmukh,Y. H. Choi,Adriana Matutino Kahn,Anne Gadomski +13 more
TL;DR: In this small blinded RCT in hospitalized COVID-19 patients, losartan did not improve outcome vs. control comparisons and was associated with adverse safety signals.